Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -3,9x - -4,3x | -4,1x |
| Selected Fwd EBIT Multiple | -2,4x - -2,6x | -2,5x |
| Fair Value | €1,30 - €1,74 | €1,52 |
| Upside | -15,3% - 13,6% | -0,8% |
| Benchmarks | Ticker | Full Ticker |
| Cytokinetics, Incorporated | CYTK | NasdaqGS:CYTK |
| Curis, Inc. | CRIS | NasdaqCM:CRIS |
| Neurogene Inc. | NGNE | NasdaqGM:NGNE |
| XOMA Royalty Corporation | XOMA | NasdaqGM:XOMA |
| Karyopharm Therapeutics Inc. | KPTI | NasdaqGS:KPTI |
| Armata Pharmaceuticals, Inc. | TG1N | DB:TG1N |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| CYTK | CRIS | NGNE | XOMA | KPTI | TG1N | ||
| NasdaqGS:CYTK | NasdaqCM:CRIS | NasdaqGM:NGNE | NasdaqGM:XOMA | NasdaqGS:KPTI | DB:TG1N | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | -13.6% | 14.1% | -46.5% | 4.0% | 10.2% | -1.6% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -3658.8% | -404.8% | -8560.8% | -185.1% | -103.4% | -4332.4% | |
| Prior Fiscal Year | -6589.7% | -482.2% | NA | -493.1% | -88.7% | -902.8% | |
| Latest Fiscal Year | -2902.7% | -408.3% | -8919.5% | -127.7% | -82.2% | -820.2% | |
| Latest Twelve Months | -2943.3% | -377.0% | -9701.2% | -54.6% | -83.7% | -859.7% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 196.78x | 3.28x | -54.51x | 8.18x | 1.61x | 41.57x | |
| EV / LTM EBITDA | -6.8x | -0.9x | 0.6x | -15.5x | -1.9x | -5.0x | |
| EV / LTM EBIT | -6.7x | -0.9x | 0.6x | -15.0x | -1.9x | -4.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -15.0x | -1.9x | 0.6x | ||||
| Historical EV / LTM EBIT | -6.1x | -4.6x | -1.8x | ||||
| Selected EV / LTM EBIT | -3.9x | -4.1x | -4.3x | ||||
| (x) LTM EBIT | (40) | (40) | (40) | ||||
| (=) Implied Enterprise Value | 158 | 167 | 175 | ||||
| (-) Non-shareholder Claims * | (123) | (123) | (123) | ||||
| (=) Equity Value | 35 | 44 | 52 | ||||
| (/) Shares Outstanding | 36.2 | 36.2 | 36.2 | ||||
| Implied Value Range | 0.98 | 1.21 | 1.44 | ||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.84 | 1.03 | 1.23 | 1.53 | |||
| Upside / (Downside) | -45.3% | -32.5% | -19.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | CYTK | CRIS | NGNE | XOMA | KPTI | TG1N | |
| Enterprise Value | 3,782 | 37 | (50) | 350 | 228 | 188 | |
| (+) Cash & Short Term Investments | 938 | 20 | 293 | 93 | 70 | 12 | |
| (+) Investments & Other | 151 | 0 | 0 | 1 | 0 | 0 | |
| (-) Debt | (910) | (34) | (12) | (114) | (260) | (135) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (0) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,960 | 23 | 230 | 329 | 38 | 65 | |
| (/) Shares Outstanding | 119.4 | 10.5 | 14.3 | 12.0 | 8.6 | 36.2 | |
| Implied Stock Price | 33.16 | 2.17 | 16.16 | 27.49 | 4.39 | 1.79 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 33.16 | 2.17 | 16.16 | 27.49 | 4.39 | 1.53 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |